Evidence map›Paper›PMID 28033130›Full record

Trial reportJournal of hypertension2017

The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial.

Ciaran J McMullan, Lea Borgi, Gary C Curhan, Naomi Fisher, John P Forman

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 5 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. The effect of cholecalciferol supplementation on allograft function in incident kidney transplant recipients: A randomized controlled study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ciaran J McMullanaRenal Division bChanning Division of Network Medicine cDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Lea Borgi
Gary C Curhan
Naomi Fisher
John P Forman
Brigham and Women's Hospital · USArena Pharmaceuticals (United States) · US

Funding

MODifiable Effectors of Renin System Activation: Treatment EvaluationR01HL105440 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FORMAN, JOHN P · 2011 to 2015
$3.5M
Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and HypertensionR01HL102122 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FORMAN, JOHN P, SESSO, HOWARD D · 2011 to 2016
$3.3M
NHLBI NIH HHS R01 HL102122NHLBI NIH HHS R01 HL105440
6 · The paper itself

Abstract

objectiveDisruption of vitamin D signaling in rodents causes activation of the rennin-angiotensin system (RAS) and development of hypertension. Observational studies in humans found lower circulating 25-hydroxyvitamin D [25(OH)D] is associated with increased RAS activity and blood pressure (BP). We performed the first randomized control trial to investigate the effects of vitamin D supplementation on the RAS in humans.

methodsVitamin D deficient, [25(OH)D ≤20 ng/ml), overweight individuals without hypertension were randomized into a double-blind, placebo-controlled trial of 8-weeks treatment with ergocalciferol or placebo. Kidney-specific RAS activity, measured using renal plasma flow response to captopril in high sodium balance, was assessed at baseline and 8 weeks, as was systemic RAS activity and 24-h ambulatory BP.

resultsIn total, 84 participants completed the study. Mean 25[OH]D levels increased from 14.7 to 30.3 ng/ml in the ergocalciferol group, P value < 0.0001, and from 14.3 to 17.4 ng/ml in the placebo group, P value = 0.3. The renal plasma flow response to captopril was 33.9 ± 56.1 ml/min per 1.73 m at baseline and 35.7 ± 47.7 ml/min per 1.73 m at 8 weeks in the ergocalciferol group (P value = 0.83); and was 37.3 ± 46.9 ml/min per 1.73 m at baseline and 35.9 ± 26.2 ml/min per 1.73 m at 8 weeks in the placebo group (P value = 0.78). Ergocalciferol had no effect on PRA, AngII, or 24-h BP measurements.

conclusionsThis trial found no benefit from correcting vitamin D deficiency on RAS activity or BP after 8 weeks. These findings are not consistent with the hypothesis that vitamin D is a modifiable target for lowering BP in vitamin D deficient individuals.

Indexed as

AdultAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCaptoprilDietary SupplementsDouble-Blind MethodErgocalciferolsFemaleHumansMaleMiddle AgedOverweightRenal CirculationRenin-Angiotensin SystemVitamin D25-hydroxyvitamin DAntihypertensive AgentsCaptoprilErgocalciferolsVitamin DVitamins

Identifiers

PMID28033130
PMCPMC5893307
OpenAlexW2563940002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.